T1	PROC 45 80	Ensayo clínico fase 4, aleatorizado
T2	PROC 272 281	biterapia
#1	AnnotatorNotes T2	C0009429; Combined Modality Therapy; Therapeutic or Preventive Procedure
T3	PROC 162 185	terapia antirretroviral
#2	AnnotatorNotes T3	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T4	CHEM 203 230	inhibidores de la integrasa
#3	AnnotatorNotes T4	C0376601; Integrase Inhibitors; Biologically Active Substance · Pharmacologic Substance
T5	CHEM 239 247	análogos
#4	AnnotatorNotes T5	C0243071; Analog; Chemical Viewed Structurally
T6	CHEM 283 295	dolutegravir
#5	AnnotatorNotes T6	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
T7	CHEM 300 310	lamivudina
#6	AnnotatorNotes T7	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T8	CHEM 313 322	darunavir
#7	AnnotatorNotes T8	C1435444; darunavir; Organic Chemical · Pharmacologic Substance
T9	CHEM 323 333	cobicistat
#8	AnnotatorNotes T9	C3177235; cobicistat; Organic Chemical · Pharmacologic Substance
T10	CHEM 338 348	lamivudina
#9	AnnotatorNotes T10	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T11	DISO 367 387	infección por el VIH
#10	AnnotatorNotes T11	C0019693; HIV Infections; Disease or Syndrome
T12	DISO 392 399	viremia
#11	AnnotatorNotes T12	C0042749; Viremia; Disease or Syndrome
T13	DISO 475 495	infección por el VIH
#12	AnnotatorNotes T13	C0019693; HIV Infections; Disease or Syndrome
T14	PROC 499 510	tratamiento
#13	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 535 542	terapia
#14	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	ANAT 572 578	sangre
#15	AnnotatorNotes T16	C0005767; Blood; Body Substance
T17	DISO 642 662	infección por el VIH
#16	AnnotatorNotes T17	C0019693; HIV Infections; Disease or Syndrome
T18	PROC 666 677	tratamiento
#17	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	PROC 709 716	terapia
#18	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	DISO 719 726	viremia
#19	AnnotatorNotes T20	C0042749; Viremia; Disease or Syndrome
T21	DISO 798 818	infección por el VIH
#20	AnnotatorNotes T21	C0019693; HIV Infections; Disease or Syndrome
T22	PROC 849 876	tratamiento antirretroviral
#21	AnnotatorNotes T22	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T23	CHEM 994 1002	fármacos
#22	AnnotatorNotes T23	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T24	DISO 1018 1042	Infecciones oportunistas
#23	AnnotatorNotes T24	C0029118; Opportunistic Infections; Disease or Syndrome
T25	CHEM 170 185	antirretroviral
#24	AnnotatorNotes T25	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T26	DISO 563 578	virus en sangre
T27	CHEM 861 876	antirretroviral
#25	AnnotatorNotes T27	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T28	DISO 940 965	mutaciones de resistencia
T29	Date 13 17	2016
T30	LIVB 353 362	pacientes
#26	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	LIVB 453 470	Pacientes adultos
#27	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group + C0001675; Adult; Age Group
T33	Duration 514 523	≥ 6 meses
T34	Neg_cue 545 548	sin
T35	LIVB 563 568	virus
#28	AnnotatorNotes T35	C0042776; Virus; Virus
T36	Duration 587 594	≥ 1 año
T37	LIVB 620 637	Pacientes adultos
#29	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group + C0001675; Adult; Age Group
T39	Duration 687 696	≥ 6 meses
T40	Duration 748 755	≥ 1 año
T41	LIVB 784 793	Pacientes
#30	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Age 826 835	≥ 18 años
T43	Date 889 899	01/01/2013
T46	PHYS 111 123	recuperación
#31	AnnotatorNotes T46	C2004454; Recovery - healing process; Organism Function
T47	LIVB 384 387	VIH
#32	AnnotatorNotes T47	C0019682; HIV; Virus
T48	LIVB 492 495	VIH
#33	AnnotatorNotes T48	C0019682; HIV; Virus
T49	LIVB 659 662	VIH
#34	AnnotatorNotes T49	C0019682; HIV; Virus
T50	LIVB 815 818	VIH
#35	AnnotatorNotes T50	C0019682; HIV; Virus
A1	Population_data T31 Age
A2	Assertion T26 Negated
A3	Population_data T37 Age
#36	AnnotatorNotes T1	C0282462; Phase 4 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity
#37	AnnotatorNotes T26	C0042749; Viremia; Disease or Syndrome
T32	Observation 98 104	efecto
#38	AnnotatorNotes T32	C1518681; Outcome of Therapy; Finding (?)
R1	Used_for Arg1:T25 Arg2:T3	
R2	Causes Arg1:T3 Arg2:T32	
T38	Quantifier_or_Qualifier 124 136	inmunológica
#39	AnnotatorNotes T38	C0205470; immunologic; Functional Concept 
R3	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T38	
T44	Quantifier_or_Qualifier 186 192	triple
#40	AnnotatorNotes T44	C0205449; Three; Quantitative Concept 
R4	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T44	
R5	Used_for Arg1:T4 Arg2:T3	
R7	Used_for Arg1:T6 Arg2:T2	
R8	Combined_with Arg1:T6 Arg2:T7	
R9	Used_for Arg1:T8 Arg2:T2	
R10	Combined_with Arg1:T8 Arg2:T9	
R11	Combined_with Arg1:T9 Arg2:T10	
R12	Causes Arg1:T47 Arg2:T11	
R13	Causes Arg1:T47 Arg2:T12	
T45	Quantifier_or_Qualifier 400 412	indetectable
#41	AnnotatorNotes T45	C3827727; Undetectable; Clinical Attribute
R14	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T45	
T51	Quantifier_or_Qualifier 413 431	de forma mantenida
#42	AnnotatorNotes T51	C0443318; Sustained; Functional Concept
R15	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T51	
R16	Experiences Arg1:T30 Arg2:T32	
R17	Experiences Arg1:T30 Arg2:T46	
R18	Experiences Arg1:T30 Arg2:T3	
R19	Combined_with Arg1:T4 Arg2:T5	
T52	Quantifier_or_Qualifier 235 238	dos
#43	AnnotatorNotes T52	C0205448; Two; Quantitative Concept 
R20	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T52	
R6	Experiences Arg1:T30 Arg2:T2	
R21	Experiences Arg1:T30 Arg2:T11	
R22	Experiences Arg1:T30 Arg2:T12	
R23	Experiences Arg1:T31 Arg2:T13	
R24	Causes Arg1:T48 Arg2:T13	
R25	Experiences Arg1:T31 Arg2:T14	
R26	Has_Duration_or_Interval Arg1:T14 Arg2:T33	
T53	Quantifier_or_Qualifier 528 534	triple
#44	AnnotatorNotes T53	C0205449; Three; Quantitative Concept
R27	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T53	
R28	Experiences Arg1:T31 Arg2:T15	
R29	Has_Duration_or_Interval Arg1:T15 Arg2:T33	
R30	Negation Arg1:T34 Arg2:T26	
R31	Causes Arg1:T35 Arg2:T26	
R32	Location_of Arg1:T16 Arg2:T26	
R33	Has_Duration_or_Interval Arg1:T26 Arg2:T36	
R34	Experiences Arg1:T31 Arg2:T26	
R35	Experiences Arg1:T37 Arg2:T17	
R36	Causes Arg1:T49 Arg2:T17	
R37	Experiences Arg1:T37 Arg2:T18	
R38	Experiences Arg1:T37 Arg2:T19	
T54	Quantifier_or_Qualifier 702 708	triple
#45	AnnotatorNotes T54	C0205449; Three; Quantitative Concept
R39	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T54	
R40	Has_Duration_or_Interval Arg1:T18 Arg2:T39	
R41	Experiences Arg1:T37 Arg2:T20	
R42	Has_Duration_or_Interval Arg1:T20 Arg2:T40	
T55	Quantifier_or_Qualifier 727 739	indetectable
#46	AnnotatorNotes T55	C3827727; Undetectable; Clinical Attribute
R43	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T55	
T56	Quantifier_or_Qualifier 678 685	estable
#47	AnnotatorNotes T56	C0205360; Stable status; Qualitative Concept
R44	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T56	
R45	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T56	
R46	Has_Duration_or_Interval Arg1:T19 Arg2:T39	
R47	Experiences Arg1:T41 Arg2:T21	
R48	Causes Arg1:T50 Arg2:T21	
R49	Has_Age Arg1:T41 Arg2:T42	
R50	After Arg1:T22 Arg2:T43	
R51	Used_for Arg1:T27 Arg2:T22	
T57	Quantifier_or_Qualifier 966 973	mayores
#48	AnnotatorNotes T57	C0205164; Major; Qualitative Concept 
R52	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T57	
T58	CONC 1071 1080	inclusión
#49	AnnotatorNotes T58	C1512693; Inclusion Criteria; Qualitative Concept
R53	Overlap Arg1:T24 Arg2:T58	
T59	Quantifier_or_Qualifier 1043 1050	activas
#50	AnnotatorNotes T59	C0679217; Active State; Idea or Concept
R54	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T59	
R55	Before Arg1:T11 Arg2:T46	
#51	AnnotatorNotes T28	C5704646; Drug resistance mutation; Cell or Molecular Dysfunction
A4	Experiencer T41 Patient
A5	Experiencer T30 Patient
A6	Experiencer T31 Patient
A7	Experiencer T37 Patient
